Skip to content
Precision for Medicine
Breaking News

Precision Wins Fierce CRO Award for Innovative Solutions in Drug Development

Category Hero Image image 35

Execute Clinical Trial Feasibility with Precision

Optimize your study's initiation through precise country and site selection, powered by actionable insights.
At Precision, our feasibility process is more than just a preliminary step; it's a critical foundation for the success of your clinical trial. By focusing on strategic site selection and in-depth insights gathering, we ensure your study starts with a significant advantage. 
iStock-876250496

Plan for success with Site Feasibility

Site feasibility is the cornerstone of clinical trial planning, acting as the bridge between groundbreaking research and its successful execution. Understanding the pivotal role of site feasibility ensures a solid foundation for any clinical study. It's not merely about identifying potential sites but about strategic alignment with the trial's objectives, patient populations, and operational capacities. This proactive approach to site selection, grounded in data-driven insights and comprehensive evaluations, mitigates risks and sets the stage for successful patient enrollment and study outcomes.

Roughly 80% of clinical trials fail to meet original enrollment timelines, and about one-third of Phase III study terminations are due to enrollment difficulties. Additionally, 15% to 20% of sites never enroll a single patient.

Given these statistics, it's evident that conducting a comprehensive feasibility study is essential for avoiding common pitfalls like poor enrollment and sites that never enroll.  Precision's feasibility team employs multiple methods to ensure a sponsor's needs are met, tailoring our approach to each unique trial. This adaptability, combined with a deep understanding of the intricacies of clinical trials, allows Precision to navigate complex requirements and ensure trials are set up for success from the start.

Precision's Clinical Trial Feasibility process overview

Step 1

Initial Planning
  • Understand study objectives
  • Identify target countries/sites
  • Develop feasibility questionnaire
  • Augment site list with Precision/external data
  • Site list finalized for feasibility start

Step 2

Data Collection & Analysis
  • Distribute questionnaires
  • Pursue sites for response
  • Collect sites responses
  • Evaluate sites performance
  • Prepare feasibility report
  • Review report with client
  • Filter out low-potential sites

Step 3

Recruitment Modeling
  • Develop enrollment scenarios
  • Estimate recruitment timelines
  • Project patient numbers
  • Adjust site requirements
  • Plan for contingencies
  • Present models to clients

Step 4

Site Selection & Verification
  • Confirm top-performing sites
  • Schedule pre-study visits
  • Verify site infrastructure
  • Assess staff expertise
  • Determine recruitment potential
  • Finalize site list for activation
  • Finalize back-up site list

Step 5

Performance Monitoring
  • Regular progress check-ins
  • Address emerging issues
  • Adjust recruitment plans
  • Activate backup sites
  • Ensure timeline adherence
  • Provide ongoing support

Precision’s strategic approach to clinical trial feasibility

Our approach to site feasibility is both comprehensive and meticulous. By integrating broad data analysis with site-specific insights, we ensure each trial starts on the best possible footing. Our process begins with understanding study objectives and identifying optimal countries and sites, followed by developing and distributing targeted feasibility questionnaires. We then analyze site responses and performance, preparing detailed feasibility reports for client review. Through recruitment modeling, we project patient numbers and timelines, allowing for adjustments and contingency planning. Site selection is confirmed through pre-study visits and infrastructure verification, with backup sites identified for risk mitigation. Continuous performance monitoring ensures adherence to timelines and proactive issue resolution, backed by ongoing support. This strategic and detailed approach enables our sponsors to navigate trial complexities with confidence, ensuring successful study execution.

Our site feasibility services can be executed during pre-study phases or integrated into full study start-up processes. This flexibility allows us to adapt to each sponsor's unique requirements, providing tailored support that aligns with their specific clinical trial needs.

Insights from Precision’s experts

Stay ahead with the latest insights from Precision’s team of experts. Discover valuable perspectives, updates, and strategies to navigate early and late phase development. 

Read: Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss

Clinical Trials - Oncology - Cell Therapies

Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1716454310949, hs_published_at=1748379090824, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins-White-150x150.jpeg',altText='Alexis-Hobbins-White-150x150',fileId=164710912635}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White

Discover
Read: Phase 1 Clinical Trial Designs Explained: BOIN, CRM, BLRM & Modern Adaptive Strategies Phase 1 Clinical Trial Designs Explained: BOIN, CRM, BLRM & Modern Adaptive Strategies

Clinical Trials

Phase 1 Clinical Trial Designs Explained: BOIN, CRM, BLRM & Modern Adaptive Strategies

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Kurt Preugschat avatar

    Kurt Preugschat

Discover
Read: Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM) Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

Clinical Trials

Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Kurt Preugschat avatar

    Kurt Preugschat

Discover

Advance therapeutic breakthroughs with Precision

Explore the breadth of our expertise in therapeutics and modalities, as we lead your novel treatments in Oncology, Rare Diseases and beyond, from the groundbreaking idea to clinical realization.

Clinical trial excellence: Precision in all phases

With people across 70+ countries, our team provides comprehensive clinical trial services that streamline and accelerate drug development at a global scale

  • Explore

    Early Phase Excellence

    Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy.
    Explore
  • Explore

    Late Phase Success

    Discover the path to market with our Late Phase Development expertise – delivering precision, scale, and efficiency for your clinical journey.
    Explore

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore